Ophthalmic Drug CDMO Market

Ophthalmic Drug CDMO Market Analysis and Forecast by Fact.MR

According to Fact.MR estimates, the global ophthalmic drug cdmo market market was valued at USD 385.0 billion in 2025. The market is projected to reach USD 418.9 billion in 2026 and is expected to grow to USD 973.6 billion by 2036, expanding at a CAGR of 8.8%. Drug Product Manufacturing Services is anticipated to account for 52.0% of the product segment in 2026, while Eye Drops & Solutions is expected to remain the leading application with around 46.0% share.

Summary of Ophthalmic Drug CDMO Market

• Market Snapshot
  • The ophthalmic drug cdmo market was valued at USD 384.96 million in 2025.
  • By 2036, the Ophthalmic Drug CDMO Market market is expected to be worth USD 973.60 million.
  • From 2026 to 2036, the market is projected to expand at a CAGR of 8.8%.
  • The market is projected to create an incremental opportunity of USD 554.72 million between 2026 and 2036.
  • In 2026, drug product manufacturing services are expected to account for 52% of the product segment, driven by sterile fill-finish and eye drop manufacturing demand.
  • The USA (10.1%) and Germany (9.6%) are two of the fastest growing markets in the world.
• Demand and Growth Drivers
  • Demand is shaped by expanding ophthalmic drug pipelines across glaucoma, dry eye disease, retinal disorders, and specialty ophthalmic indications from pharma and biotech developers.
  • Growth reflects pharmaceutical company preference for specialty CDMO partners with sterile fill-finish capability and ophthalmic-specific formulation expertise.
  • Adoption is increasing due to rising complexity of ophthalmic drug delivery including sustained release implants, preservative-free multi-dose systems, and intravitreal injection formulations.
• Product and Segment View
  • Drug product manufacturing services lead the product segment with a 52% share in 2026, supported by sterile fill-finish and eye drop manufacturing capacity demand.
  • Eye drops and solutions hold 46% of the application segment, anchored by glaucoma treatment and dry eye disease formulation volumes.
  • Pharmaceutical companies account for 58% of end-use demand, while generic drug manufacturers, biotechnology companies, and ophthalmic biotech firms form secondary channels.
• Geography and Competitive Outlook
  • North America remains the largest regional market, supported by strong ophthalmic pharma pipeline activity, mature CDMO partnership models, and established specialty manufacturing infrastructure.
  • Europe follows closely, led by Germany where strong pharma manufacturing infrastructure and specialty ophthalmic drug development both support CDMO demand.
  • The competitive field is led by Lonza Group with an estimated 33.9% share, followed by Catalent Inc., Recipharm AB, Siegfried Holding, and Piramal Pharma Solutions.
• Analyst Opinion
  • The ophthalmic drug CDMO market represents a specialized pharmaceutical outsourcing segment where technical capability barriers protect premium margin economics, and the commercial positioning reflects this specialty character. The category is structurally attractive because ophthalmic drug formulations require sterile manufacturing capability, specialty primary packaging including multi-dose dropper systems, and formulation expertise spanning solutions, ointments, gels, and increasingly sustained-release implants. The commercial lever that matters most is integrated development and manufacturing capability because pharma customers increasingly prefer CDMO partners that can handle preformulation development, clinical trial material manufacturing, and commercial-scale production through single engagements. Players that combine deep sterile manufacturing capability with ophthalmic-specific formulation and packaging expertise will capture premium positioning, while generalist CDMO competitors without specialty ophthalmic capabilities face pressure as pharma customers consolidate ophthalmic work with specialist providers.

Why is Ophthalmic Drug CDMO Market Growing?

• Growth reflects expanding ophthalmic drug pipelines across glaucoma, dry eye disease, retinal disorders, and specialty ophthalmic indications.
• Demand is shaped by pharmaceutical company preference for specialty CDMO partners with sterile fill-finish capability and ophthalmic formulation expertise.
• Adoption is increasing due to rising complexity of ophthalmic drug delivery systems including sustained release implants and intravitreal injection formulations.

The demand base rests on expanding ophthalmic drug pipelines across multiple therapeutic categories. Glaucoma treatment remains the largest indication by volume, with ongoing formulation innovation around once-daily dosing, preservative-free options, and sustained-release drug delivery. Dry eye disease treatment has expanded substantially following new product approvals from companies such as Novartis, AbbVie, and specialty ophthalmic biotech firms. Retinal disease treatment pipelines including age-related macular degeneration, diabetic macular edema, and geographic atrophy continue producing new biologic and small-molecule product candidates requiring specialty CDMO capability.

The second structural driver is pharmaceutical company preference for specialty CDMO partners. Ophthalmic drug manufacturing requires specialty sterile fill-finish capability, expertise in ophthalmic-specific primary packaging including multi-dose dropper systems, and formulation expertise across solutions, ointments, and gels. Pharma companies increasingly prefer CDMO partners with dedicated ophthalmic capability rather than generalist sterile manufacturers, which concentrates demand at specialty providers such as Lonza Group, Catalent Inc., Recipharm AB, and other specialists.

The third driver is rising complexity of ophthalmic drug delivery. Sustained-release implants such as Durysta (AbbVie) and Yutiq, preservative-free multi-dose systems, and intravitreal injection formulations all require specialty manufacturing capability beyond traditional eye drop production. As ophthalmic drug delivery technology continues advancing, the technical capability bar for CDMO participation rises, which supports premium pricing for specialty providers with sustained investment in advanced formulation and manufacturing capabilities.

Segment-wise Analysis of Ophthalmic Drug CDMO Market

• Drug product manufacturing services lead the product segment with 52% share in 2026, anchored by sterile fill-finish and eye drop manufacturing volumes.
• Drug development services represent a fast-growing sub-segment, driven by pharma preference for integrated development and manufacturing engagements.
• Eye drops and solutions hold 46% of the application segment, followed by ointments and gels, injectable ophthalmics, and implants and inserts as secondary use cases.

The segmentation view shows a category where drug product manufacturing dominates volume while integrated development and manufacturing engagements drive premium growth. Competitive advantage rests on sterile fill-finish capability depth, ophthalmic-specific formulation expertise, and integrated development and manufacturing capability. Growth over the forecast period is expected to tilt toward injectable ophthalmics and implant and insert manufacturing as advanced drug delivery technology adoption expands.

Why Do Drug Product Manufacturing Services Lead the Product Segment?

Drug product manufacturing services lead the product segment because they represent the largest share of ophthalmic CDMO contract value. Sterile fill-finish services for eye drops, ointments, gels, and injectable ophthalmics all fall under this segment and drive the majority of recurring manufacturing revenue. Commercial-scale manufacturing of approved ophthalmic drugs generates sustained multi-year contracts that anchor CDMO revenue, while clinical trial material manufacturing contracts also contribute to drug product manufacturing service volume.

The segment leadership is reinforced by capacity investment economics. Specialty ophthalmic manufacturing facilities require substantial capital investment in sterile manufacturing capability, specialty primary packaging equipment, and regulatory-compliant quality systems. These investments create meaningful barriers to entry that protect existing specialty providers' pricing positions, which supports sustained segment leadership. Lonza Group, Catalent Inc., and other leading providers continue investing in sterile fill-finish capacity expansion to serve growing pharma demand.

Why are Drug Development Services a Fast-Growing Sub-Segment?

Drug development services are a fast-growing sub-segment because pharmaceutical and biotechnology companies increasingly prefer integrated development and manufacturing engagements with single CDMO partners. Preformulation and formulation development work for new ophthalmic drugs naturally leads to clinical trial material manufacturing and eventually commercial-scale production at the same facility, which supports customer retention and lifetime value expansion for CDMO providers.

Growth within drug development services is being lifted by ophthalmic biotech company activity. Specialty ophthalmic biotech firms typically lack in-house manufacturing capability and rely heavily on CDMO partners for both development and commercial manufacturing. As venture capital investment in ophthalmic biotech continues, development services contract volume expands in parallel. Rising complexity of ophthalmic drug delivery systems also increases the technical intensity of development services engagements, which supports premium pricing.

Key Growth Drivers, Constraints, and Market Scope

• Ophthalmic pipeline expansion and pharma CDMO preference for specialty partners are the structural demand foundations.
• Advanced drug delivery complexity and integrated development and manufacturing engagement growth are the key compositional shifts driving premium growth.
• Capacity constraints at specialty providers, regulatory complexity, and customer concentration remain the leading constraints.

The market scope is shaped by the combination of steady drug product manufacturing service demand and accelerating specialty development engagement growth. Competitive advantage sits in sterile fill-finish capability depth, ophthalmic-specific formulation expertise, and integrated development and manufacturing capability.

Growth Drivers

The primary driver is expanding ophthalmic drug pipelines across glaucoma, dry eye disease, retinal disorders, and specialty ophthalmic indications, which drives CDMO contract volume growth. A second driver is pharmaceutical company preference for specialty CDMO partners with sterile fill-finish capability and ophthalmic formulation expertise, which concentrates demand at specialty providers. A third driver is rising complexity of ophthalmic drug delivery systems including sustained release implants and intravitreal injection formulations, which supports premium pricing for advanced capability providers. These three forces combine to deliver a high single-digit growth trajectory with premium uplift from specialty delivery system manufacturing.

Constraints

The leading constraint is capacity constraint at specialty ophthalmic CDMO providers. Sterile fill-finish capacity is globally tight, which creates scheduling constraints and pricing power for specialty providers but also limits category growth potential. A second constraint is regulatory complexity. Ophthalmic drug manufacturing is subject to stringent FDA and EMA regulatory oversight, with facility inspections, quality system audits, and product-specific validation requirements creating ongoing compliance burden. A third constraint is customer concentration. Major pharmaceutical customers represent outsized share of CDMO revenue, which creates concentration risk and limits pricing leverage for providers against their largest customers.

Opportunities

The strongest opportunity lies in advanced drug delivery system manufacturing expansion, where premium pricing for specialty capability supports meaningful margin growth. A second opportunity is sterile fill-finish capacity expansion, where providers investing ahead of demand can capture market share as pharma customers seek reliable capacity. A third opportunity is emerging market development, particularly in India and South Korea, where specialty pharmaceutical manufacturing capability is expanding and local ophthalmic pharma activity is growing.

Regional Outlook Across Key Markets

• The USA leads country-level growth at 10.1% CAGR, supported by strong ophthalmic pharma pipeline activity, mature CDMO partnership models, and established specialty manufacturing infrastructure.
• Germany follows at 9.6%, driven by strong pharma manufacturing infrastructure and specialty ophthalmic drug development activity.
• The UK at 9.3% and Japan at 8.9% both show active specialty pharmaceutical manufacturing and ophthalmic drug development programs.
• South Korea at 8.7% and France at 8.4% both support growing specialty CDMO positioning and ophthalmic pharma manufacturing capability.

Country CAGR Table

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

Regional dynamics reflect the concentration of specialty ophthalmic CDMO activity in developed markets with strong pharmaceutical manufacturing infrastructure. The USA leads on the strength of ophthalmic pharma pipeline depth and mature CDMO partnership models. Europe, led by Germany, supports active specialty CDMO activity through established pharmaceutical manufacturing infrastructure. Asia Pacific growth is led by Japan and South Korea, where specialty pharmaceutical manufacturing capability continues expanding.

United States

The United States anchors global demand through its strong ophthalmic pharma pipeline activity, mature CDMO partnership models, and established specialty manufacturing infrastructure. AbbVie (Allergan), Novartis, Alcon, Bausch & Lomb, and specialty ophthalmic pharma and biotech companies drive substantial CDMO contract volume. Lonza Group, Catalent Inc., Thermo Fisher Scientific, and Patheon all operate US specialty ophthalmic manufacturing capacity serving domestic and export markets.

• Strong ophthalmic pharma pipeline activity drives sustained CDMO contract volume.
• Mature CDMO partnership models support integrated development and manufacturing engagements.
• Established specialty manufacturing infrastructure supports premium capability positioning.

Germany

Germany leads European specialty CDMO activity on the strength of mature pharmaceutical manufacturing infrastructure, strong specialty ophthalmic drug development activity, and established CDMO service provider presence. Recipharm AB and other European specialty CDMO providers maintain significant German manufacturing capacity. German pharmaceutical manufacturers including Bayer support domestic ophthalmic pipeline activity, while specialty biotech firms also drive CDMO demand.

• Mature pharmaceutical manufacturing infrastructure supports specialty CDMO capacity.
• Strong specialty ophthalmic drug development supports CDMO contract volume.
• Established CDMO service provider presence anchors regional capability.

United Kingdom

The United Kingdom market is shaped by active specialty pharmaceutical manufacturing, strong ophthalmic biotech activity particularly around Cambridge and Oxford clusters, and established CDMO service provider presence. GSK supports domestic ophthalmic pipeline activity, while specialty biotech firms drive additional CDMO contract volume. Almac Group and other UK-based specialty providers serve domestic and export demand.

• Active specialty pharmaceutical manufacturing supports CDMO capability positioning.
• Strong ophthalmic biotech activity in Cambridge and Oxford clusters drives contract volume.
• Established CDMO service provider presence anchors specialty capability.

Japan

Japan represents a mature specialty CDMO market shaped by strong domestic ophthalmic pharma activity including Santen Pharmaceutical and Otsuka Pharmaceutical, established specialty manufacturing infrastructure, and PMDA regulatory oversight. Santen is the global leader in ophthalmic pharmaceuticals and drives substantial specialty manufacturing demand. Japanese CDMO providers also serve export demand to other Asia Pacific markets.

• Strong domestic ophthalmic pharma activity led by Santen supports specialty CDMO demand.
• Established specialty manufacturing infrastructure supports domestic and export capability.
• PMDA regulatory oversight supports high-quality specialty manufacturing standards.

South Korea

South Korea represents a growing specialty CDMO market driven by expanding domestic pharmaceutical manufacturing capability, rising ophthalmic biotech activity, and cross-border CDMO partnerships with global pharma. Korean CDMO providers are building specialty ophthalmic capability to serve both domestic pharma customers and export opportunities particularly to other Asia Pacific markets.

• Expanding domestic pharmaceutical manufacturing supports specialty CDMO capability.
• Rising ophthalmic biotech activity drives domestic contract volume growth.
• Cross-border CDMO partnerships support export opportunity development.

France

France represents a steady specialty CDMO market shaped by Sanofi's domestic pharmaceutical activity, specialty ophthalmic biotech firms, and established CDMO service provider presence. Corden Pharma and other French-based specialty providers serve domestic and European pharma customers. French ophthalmic biotech activity supports additional CDMO contract volume.

• Sanofi's domestic pharmaceutical activity supports specialty CDMO demand.
• Specialty ophthalmic biotech firms drive additional contract volume.
• Established CDMO service provider presence anchors regional specialty capability.

Competitive Benchmarking and Company Positioning

• Lonza Group leads with an estimated 33.9% share, supported by its broad specialty CDMO portfolio, global manufacturing footprint, and integrated development and manufacturing capability.
• Catalent Inc., Recipharm AB, Siegfried Holding, and Piramal Pharma Solutions compete through differentiated specialty manufacturing capabilities and channel strength.
• Specialty players such as Thermo Fisher Scientific, Evonik Industries, Patheon, Almac Group, and Corden Pharma hold focused positions across specific service segments.

The competitive field is concentrated at the top, with Lonza Group commanding a strong share position through its broad specialty CDMO portfolio spanning development services, sterile fill-finish manufacturing, and specialty formulation capabilities. Lonza's scale reach, global manufacturing footprint, and integrated development and manufacturing capability create meaningful competitive advantages across ophthalmic CDMO engagements.

Catalent Inc. competes through its broad pharma and biotech CDMO services including specialty ophthalmic capability. Recipharm AB holds strong positions in European specialty manufacturing. Siegfried Holding and Piramal Pharma Solutions both maintain specialty ophthalmic capacity serving pharma customers globally. Thermo Fisher Scientific and Patheon compete through broader CDMO portfolios with ophthalmic capability. Evonik Industries holds specialty positions in drug delivery platform services. Almac Group, Corden Pharma, and other specialty providers maintain focused positions in specific service segments.

Strategic priorities across the field include expanding sterile fill-finish capacity, deepening ophthalmic-specific formulation expertise, and building advanced drug delivery system manufacturing capability. Scaled specialty providers with integrated development and manufacturing capability will capture the bulk of forecast period growth, while generalist CDMO competitors without specialty ophthalmic depth face pressure as pharma customers consolidate ophthalmic work with specialist partners.

Competitive Analysis

Competitive positioning rests on three dimensions: sterile fill-finish capability depth, ophthalmic-specific formulation expertise, and integrated development and manufacturing capability. Lonza Group leads across all three dimensions. Catalent Inc. competes broadly through portfolio depth. Recipharm AB and Siegfried Holding lead specialty manufacturing positioning in European markets. Evonik Industries leads specifically in drug delivery platform capability.

Second-tier competitors maintain relevance through specialty service positioning, focused therapeutic strategies, or regional channel concentration. Indian and Korean specialty CDMO providers are building capability positions in value-tier segments, particularly for generic ophthalmic drug manufacturing. The gap between integrated specialty providers with development and manufacturing capability and single-service competitors continues to widen as pharma customers consolidate CDMO partnerships.

Benchmarking Table

Recent Developments

• In 2025, Lonza Group continued expanding its specialty CDMO portfolio through capacity investments targeting sterile fill-finish and advanced drug delivery system manufacturing.
• In 2025, Catalent Inc. advanced its specialty CDMO capability through platform updates and integration with pharma customer development pipelines.
• In 2026, Recipharm AB strengthened its European specialty manufacturing capacity through targeted expansion investments supporting ophthalmic and sterile manufacturing applications.

Leading Companies Shaping Ophthalmic Drug CDMO Market

• Major Players

  • Lonza Group
  • Catalent Inc.
  • Recipharm AB
  • Siegfried Holding
  • Piramal Pharma Solutions
  • Thermo Fisher Scientific
  • Evonik Industries
  • Patheon

• Emerging Players

  • Almac Group
  • Corden Pharma
  • Vetter Pharma
  • Baxter BioPharma Solutions
  • Pfizer CentreOne
  • WuXi AppTec
  • Samsung Biologics
  • Fareva Group

Sources and Research References

• United States Food and Drug Administration (FDA) - NDA and BLA Filings for Ophthalmic Drugs
• European Medicines Agency (EMA) - Centralized Procedure Filings for Ophthalmic Products
• World Health Organization (WHO) - Essential Medicines List Ophthalmic Publications
• American Academy of Ophthalmology (AAO) - Preferred Practice Pattern Publications
• Lonza Group - Annual Report and CDMO Segment Disclosures
• Catalent Inc. - Specialty CDMO Portfolio Publications
• Primary interviews with pharma company CDMO managers, biotech company operations leaders, CDMO business development teams, and regulatory specialists

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the ophthalmic drug CDMO market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product segment is likely to lead the market by 2026?
• Which application segment will account for the highest demand by 2026?
• How is ophthalmic drug pipeline activity reshaping CDMO demand patterns?
• Why are the USA and Germany the fastest-growing markets?
• Which countries are projected to show the fastest growth through 2036?
• Who are the key companies active in the ophthalmic drug CDMO market?
• How is advanced drug delivery technology changing the competitive dynamics?

Ophthalmic Drug CDMO Market Definition

The ophthalmic drug CDMO market covers contract development and manufacturing services provided to pharmaceutical and biotechnology companies for ophthalmic drug products. This includes drug product manufacturing services such as sterile fill-finish and eye drop and solution manufacturing, drug development services including preformulation and formulation development and clinical trial material manufacturing, analytical and regulatory services including stability testing and regulatory filing support, and packaging services including ophthalmic bottle packaging and multi-dose and preservative-free systems. The market spans pharmaceutical companies, large pharma companies, generic drug manufacturers, biotechnology companies, ophthalmic biotech firms, gene therapy developers, research institutes, and clinical research organizations across product applications including eye drops and solutions, ointments and gels, injectable ophthalmics, and implants and inserts.

Ophthalmic Drug CDMO Market Inclusions

The scope includes drug product manufacturing services across sterile fill-finish services, eye drop and solution manufacturing, and ointment and gel formulation, drug development services including preformulation and formulation development and clinical trial material manufacturing, analytical and regulatory services including stability testing services and regulatory filing and compliance support, and packaging services including ophthalmic bottle packaging and multi-dose and preservative-free systems. It covers applications across eye drops and solutions for glaucoma treatment drops and dry eye disease formulations, ointments and gels including anti-infective ointments and anti-inflammatory gels, injectable ophthalmics including intravitreal injections and retinal disease treatments, and implants and inserts including sustained release implants and intraocular drug delivery systems. Coverage spans pharmaceutical companies, large pharma companies, generic drug manufacturers, biotechnology companies, ophthalmic biotech firms, gene therapy developers, research institutes, clinical research organizations, and academic research centers from 2026 to 2036.

Ophthalmic Drug CDMO Market Exclusions

The scope excludes in-house ophthalmic drug manufacturing performed by pharmaceutical companies at their own facilities without CDMO engagement. It also excludes active pharmaceutical ingredient (API) manufacturing services, which represent a separate CDMO segment with different technical and commercial dynamics. Ophthalmic medical device manufacturing services including intraocular lens production, contact lens manufacturing, and surgical instrument production are outside the scope. Diagnostic ophthalmic product development and manufacturing are also excluded, as are consumer ophthalmic products such as over-the-counter eye drops manufactured for retail channels rather than under pharma CDMO engagements.

Ophthalmic Drug CDMO Market Research Methodology

• Primary Research: Interviews with pharma company CDMO managers, biotech company operations leaders, CDMO business development teams, and regulatory specialists to validate contract structures, pricing dynamics, and capability requirements.
• Desk Research: Review of FDA NDA and BLA filings for ophthalmic drugs, CDMO company disclosures, PharmaCompass CDMO database, and published ophthalmic pharmaceutical pipeline publications.
• Market Sizing: Demand-side model built on ophthalmic drug approvals and pipeline activity, CDMO contract value estimates, per-project pricing across development and commercial manufacturing services, and capacity utilization patterns at specialty ophthalmic CDMO facilities.
• Data Validation: Cross-validation across primary interviews, CDMO financial disclosures, pharma company outsourcing spend analyses, and specialty pharmaceutical industry publications, with sensitivity analysis on ophthalmic pipeline approval rates and sterile fill-finish capacity investment.